Cellectar Biosciences
CLRB
9 hedge funds and large institutions have $782K invested in Cellectar Biosciences in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
19% less capital invested
Capital invested by funds: $961K → $782K (-$179K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$131K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$35.6K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$395K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$267K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$137K |
| 4 |
Morgan Stanley
New York
|
-$71.3K |
| 5 |
AS
Arxis Securities
New York
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $253K | +$83.2K | +14 | +61% |
|
|
2
State Street
Boston,
Massachusetts
| $147K | +$131K | +22 | New |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $122K | – | – | – |
|
|
VKH
4
Virtu KCG Holdings
New York
| $77K | -$137K | -23 | -68% |
|
|
5
Citadel Advisors
Miami,
Florida
| $43K | +$35.6K | +6 | New |
|
|
AIC
6
AWM Investment Company
New York
| $41K | – | – | – |
|
|
7
Northern Trust
Chicago,
Illinois
| $37K | +$29.7K | +5 | New |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $29K | -$267K | -45 | -92% |
|
|
9
Morgan Stanley
New York
| $29K | -$71.3K | -12 | -75% |
|
|
WAM
10
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $2K | – | – | – |
|
11
BlackRock
New York
| $1K | – | – | – |
|
12
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $1K | – | – | – |
|
|
SM
13
Sabby Management
Miami Beach,
Florida
| – | -$395K | -108 | Closed |
|
|
AS
14
Arxis Securities
New York
| – | -$20K | -5 | Closed |
|
|
AIM
15
Acrospire Investment Management
Chicago,
Illinois
| – | -$10K | -3 | Closed |
|
CLRB Hedge Fund Activity: Q1 2017 in Review
9 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2017, worth a combined $782K — down 19% from $961K a quarter earlier.
Fund positioning in CLRB was balanced in Q1 2017: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $131K. The largest seller was Sabby Management, exiting entirely with an estimated $395K sold.
- 9 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $782K of Cellectar Biosciences stock for Q1 2017, down 19% quarter-over-quarter.
- 3 funds opened new Cellectar Biosciences positions in Q1 2017 and 3 closed out, a net change of 0 holders.
- The largest Cellectar Biosciences buyer in Q1 2017 was State Street, an estimated $131K added.
- The largest Cellectar Biosciences seller in Q1 2017 was Sabby Management, an estimated $395K sold.
Based on aggregated 13F filings for Q1 2017.